Sixty-day mortality of patients with metastatic colorectal cancer randomized to systemic treatment vs primary tumor resection followed by systemic treatment. The CAIRO4 phase 3 randomized clinical trial.
van der Kruijssen DEW, Elias SG, Vink GR, van Rooijen KL, Lam-Boer J, Mol L, et al for the CAIRO4 Working Group.
JAMA Surg 2021; 156: 1093-1101.
This study included 196 patients with metastatic colorectal cancer, and few or no symptoms from the primary. At 60 days, mortality rates were higher in those who had surgery as well as chemotherapy: 3 versus 11 per cent, P=0.03.
Comment: These results are of interest, but the real question is whether additional surgery provides a later benefit.
1 January 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.